Centaurus Financial Inc. Takes $1.24 Million Position in Amgen Inc. $AMGN

Centaurus Financial Inc. bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 3,413 shares of the medical research company’s stock, valued at approximately $1,236,000.

A number of other institutional investors and hedge funds have also bought and sold shares of AMGN. Brasada Capital Management LP purchased a new position in Amgen in the 2nd quarter worth approximately $558,000. Pacific Heights Asset Management LLC purchased a new stake in Amgen during the 2nd quarter valued at approximately $32,591,000. Coastal Bridge Advisors LLC purchased a new stake in Amgen during the 2nd quarter valued at approximately $5,174,000. Jefferies Financial Group Inc. bought a new stake in shares of Amgen during the second quarter valued at approximately $86,829,000. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Amgen during the second quarter valued at approximately $76,054,000. 76.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares in the company, valued at $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 6,222 shares of company stock valued at $2,540,926. Company insiders own 0.85% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $436.99 on Friday. The firm has a fifty day simple moving average of $386.75 and a two-hundred day simple moving average of $364.23. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $447.03. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. The stock has a market capitalization of $236.25 billion, a P/E ratio of 27.16, a PEG ratio of 3.18 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analysts’ expectations of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company earned $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. On average, analysts expect that Amgen Inc. will post 22.92 earnings per share for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Stockholders of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s payout ratio is 62.65%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Tezspire posted strong Phase 3 results in eosinophilic esophagitis (EoE). The drug met both co-primary and all key secondary endpoints, producing statistically significant and clinically meaningful improvements in tissue inflammation and difficulty swallowing. Benefits were sustained through 52 weeks, supporting a potential third approved indication beyond asthma and chronic rhinosinusitis with nasal polyps. Tezspire Phase 3 results
• Positive Sentiment: The EoE opportunity could materially expand Tezspire’s commercial potential. Analysts and industry commentators view EoE as a possible blockbuster market, potentially allowing Amgen and partner AstraZeneca to compete more directly with established biologics such as Dupixent. Regulatory filing and approval remain necessary before the opportunity can translate into revenue. Tezspire EoE market opportunity
• Neutral Sentiment: Amgen began a Phase 1 study of AMG 691 aimed at a potentially important Asian market. The trial could add a long-term growth asset, but it is at an early stage and provides limited near-term earnings visibility. AMG 691 Phase 1 trial
• Negative Sentiment: Amgen ended its Crohn’s disease research collaboration with TScan Therapeutics. The decision removes an exclusive effort to identify and develop T-cell targets in inflammatory bowel disease, narrowing one element of Amgen’s early pipeline and highlighting uncertainty around its partnership strategy. Amgen ends Crohn’s disease partnership

Analysts Set New Price Targets

AMGN has been the subject of a number of research reports. Canaccord Genuity Group upped their target price on shares of Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research report on Wednesday, August 5th. Freedom Capital upgraded shares of Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. BMO Capital Markets boosted their price target on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research note on Wednesday, August 5th. TD Cowen raised their price objective on Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Finally, Wells Fargo & Company lifted their target price on Amgen from $390.00 to $400.00 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, fourteen have given a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $380.43.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.